A No-Reference Medical Image Quality Assessment Method Based on Automated Distortion Recognition Technology: Application to Preprocessing in MRI-guided Radiotherapy

Objective:To develop a no-reference image quality assessment method using automated distortion recognition to boost MRI-guided radiotherapy precision.Methods:We analyzed 106,000 MR images from 10 patients with liver metastasis,captured with the Elekta Unity MR-LINAC.Our No-Reference Quality Assessment Model includes:1)image preprocessing to enhance visibility of key diagnostic features;2)feature extraction and directional analysis using MSCN coefficients across four directions to capture textural attributes and gradients,vital for identifying image features and potential distortions;3)integrative Quality Index(QI)calculation,which integrates features via AGGD parameter estimation and K-means clustering.The QI,based on a weighted MAD computation of directional scores,provides a comprehensive image quality measure,robust against outliers.LOO-CV assessed model generalizability and performance.Tumor tracking algorithm performance was compared with and without preprocessing to verify tracking accuracy enhancements.Results:Preprocessing significantly improved image quality,with the QI showing substantial positive changes and surpassing other metrics.After normalization,the QI's average value was 79.6 times higher than CNR,indicating improved image definition and contrast.It also showed higher sensitivity in detail recognition with average values 6.5 times and 1.7 times higher than Tenengrad gradient and entropy.The tumor tracking algorithm confirmed significant tracking accuracy improvements with preprocessed images,validating preprocessing effectiveness.Conclusions:This study introduces a novel no-reference image quality evaluation method based on automated distortion recognition,offering a new quality control tool for MRIgRT tumor tracking.It enhances clinical application accuracy and facilitates medical image quality assessment standardization, with significant clinical and research value.